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A Rare Case of Spontaneous Remission and Relapse of a 
Primary Central Nervous System Lymphoma 
Caso Raro de Remissão Espontânea e Posterior Recidiva 
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ABSTRACT
Primary central nervous system lymphoma remission after steroid treatment is a well-known phenomenon, but remission without any 
type of treatment is extremely rare. We present a rare case of spontaneous remission of a diffuse large B-cell lymphoma of the central 
nervous system as well as its subsequent reappearance in another location. The atypical presentation misled the neurosurgeons and 
neurologists, delaying diagnosis and treatment. The patient underwent brain biopsy after the relapse and started radiotherapy and 
chemotherapy with cytarabine + methotrexate + rituximab. As of 32 months after the diagnosis, the patient remained asymptomatic, 
with no focal neurological deficits and the disease in complete remission. A PubMed search of the literature up to June 2017 regarding 
spontaneous remission central nervous system lymphoma was also carried out.
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RESUMO
É bem conhecida a remissão com corticoterapia dos linfomas primários do sistema nervoso central, mas a sua remissão sem qual-
quer tipo de tratamento é extremamente rara. Apresentamos um caso raro de uma remissão espontânea e posterior recidiva noutra 
localização de um linfoma difuso de grandes células B do sistema nervoso central. A apresentação atípica deste caso confundiu os 
neurocirurgiões e neurologistas, atrasando o diagnóstico e tratamento. A doente foi submetida a biópsia de uma das lesões cerebrais 
e, posteriormente, iniciou radioterapia e quimioterapia com citarabina + metotrexato + rituximab. Neste momento, 32 meses após o 
diagnóstico histológico, a doente encontra-se assintomática, sem défices neurológicos focais e com remissão completa da doença. Foi 
também efetuada uma pesquisa na PubMed até junho de 2017 sobre a remissão espontânea dos linfomas do sistema nervoso central. 
Palavras-chave: Linfoma/quimioterapia; Linfoma/radioterapia; Neoplasias do Sistema Nervoso Central/quimioterapia; Neoplasias do 
Sistema Nervoso Central/radioterapia
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INTRODUCTION
 Malignant lymphomas can affect the central nervous 
system (CNS) in three ways: as primary CNS lymphoma, as 
a consequence of systemic lymphoma, and by intravascular 
lymphomatosis.1
 Primary CNS lymphoma is a rare form of extranodal 
non-Hodgkin’s lymphoma.2,3 Its incidence has increased 
in both immunocompetent and immunodeficient patients, 
and currently accounts for about 2.2% of all intracranial tu-
mors4,5 and 1% - 2% of all lymphomas.6 Most cases are 
sporadic, with a minority associated with cases of immuno-
deficiencies including human immunodeficiency virus (HIV) 
and iatrogenic immunosuppression.4
 Primary CNS lymphoma can affect individuals of all 
ages, with a peak incidence in immunocompetent patients 
occurring between the fifth and seventh decades of life5 and 
with a mean age of 60 years.2
 The clinical manifestations vary depending on the loca-
tion of the lesion. The most common symptoms are psychi-
atric changes, headaches, seizures, ocular symptoms and 
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 The most sensitive imaging technique is magnetic reso-
nance imaging (MRI), and they frequently appear as a high-
cellular lesion, iso- or hypo-intense in T1 weighted images,8 
with hypersignal in T2-weighted images and intense con-
trast uptake.5 The lesions are solitary in 65% of cases and 
multiple in the remaining cases.5
 The most frequent location is in the cerebral hemi-
spheres, followed by the basal ganglia, corpus callosum 
and cerebellum.9 However, there are no specific features 
that distinguish them from other primary or secondary brain 
neoplasms.2
 The most used diagnostic method is a lesion biopsy and 
90% – 95% are histologically classified as diffuse large B-
cell lymphoma.4
 Treatment of primary CNS lymphoma, as with other 
brain neoplasms, involves surgery, radiotherapy (RT), and 
chemotherapy (CT), with the latter two being the modalities 
of choice. The role of surgery is mainly diagnostic. How-
ever, some recent studies have reported a better prognosis 
in radical surgical removal of single lesions in non-eloquent 
brain areas. The role of RT has lost importance in recent 
years. Holocranial RT achieves high response rates but the 
duration of the effect is short and neurotoxicity is high. CT 
is the first therapeutic choice for newly diagnosed primary 
lymphomas of the CNS. It allows for high response rates 
and long periods without symptoms. The most commonly 
used drug is high-dose methotrexate alone or in combina-
tion with high-dose of cytarabine, procarbazine, vincristine 
and rituximab. A 2009 study reported a better response with 
methotrexate + cytarabine compared with methotrexate 
monotherapy.2
 In the past, primary CNS lymphoma prognoses were 
typically poor, but today, long-term survival of up to 10 years 
with certain treatment regimens is not uncommon,10 and 
cure can be achieved in some patients.11
 Brain lymphoma remission after corticosteroid therapy 
is well documented9 and they are the most frequent cause 
of “phantom tumor”. Other causes exist for the same phe-
nomenon such as multiple sclerosis, disseminated acute 
encephalomyelitis, sarcoidosis and also gliomas.12 Theories 
that best explain this remission are that corticosteroids in-
duce lymphocytic effects, repair of the blood–brain barrier, 
and the vasoconstriction that leads to a decrease in tumor 
blood supply.13
 When a primary CNS lymphoma is suspected, corticos-
teroid therapy should be postponed until histological results 
are reviewed because imaging and clinical remission may 
delay diagnosis and initiation of treatment.
 Spontaneous remission of brain lymphomas without 
corticosteroid therapy is extremely rare. This type of re-
mission may raise other diagnostic hypotheses, namely 
inflammatory and demyelinating diseases and again lead 
to a delay in diagnosis and treatment. The most plausible 
explanation for this phenomenon is based on an immune 
theory9,13,14 with changes in the host immunologic compe-
tence in which there is an increase in the body number of 
natural killer cells that may be caused by a concomitant viral 
infection. These natural killer cells then eliminate tumor lym-
phomatous cells.9
 We present a report of a tumor that vanished without 
corticosteroid treatment. The diagnosis and treatment of the 
tumor was delayed because brain lymphoma was only sus-
pected after the second brain MRI.
CASE REPORT
 A 50-year-old female patient, medicated with a seroto-
nin reuptake inhibitor (escitalopram), bromazepam and oral 
contraceptive was asymptomatic until January 2014, when 
Figure 1 – Initial CT scan in January 2014, before (A) and after (B) IV contrast. A suprasellar lesion with 3 cm in diameter is seen in booth. 
The mass involves the optic chiasm and enhances after contrast administration.
A B
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she began to complain of blurred vision. She underwent 
ophthalmologic evaluation and ocular correction was per-
formed. A computed tomography (CT) scan revealed a 3 
cm suprasellar hyperdense lesion (Figs. 1A and 1B). A hor-
monal study revealed prolactin values (PRL) of 183 ng/mL 
and she was referred to a pituitary disease multidisciplinary 
consultation for suspected macroprolactinoma.
 Brain MRI was performed in May 2014 (Figs 2A to 2D), 
without any type of medication and after clinical improve-
ment of the visual complaints. The MRI showed remission 
of the suprasellar lesion, but also showed two new nodular 
lesions, with the largest in the right caudate nucleus with 
subependymal expression, and the other in the anterior part 
of the third ventricle. A new hormonal study was performed, 
with no treatment having been given, and the prolactin lev-
els were 76 ng/mL. The macroprolactinoma hypothesis was 
set aside and the patient was referred for neurologic consul-
tation for suspected inflammatory disease.
Figure 2 – Initial MRI in May 2014. T1 axial weighted images with gadolinium enhancement demonstrate involution of the sellar / supra-
sellar lesion (A and B). Axial T1 weighted image with gadolinium enhancement shows nodular lesion with homogeneous contrast uptake 
in the head of the right caudate nucleus and with subependymal expression (C). Axial T1 weighted images with gadolinium enhancement 
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 In August 2014, the patient again began to experience 
reduced visual acuity, and a new MRI was performed with-
out any treatment given (Figs. 3A to 3D). MRI revealed re-
gression of the lesion in the anterior portion of the third ven-
tricle, and marked enlargement of the right caudate nucleus 
periventricular lesion. CNS lymphoma was hypothesized, 
despite some atypical features, and the patient was referred 
for neurosurgical consultation.
 In October 2014, the patient underwent a right caudate 
nucleus lesion biopsy guided by neuronavigation. The his-
tological result revealed a diffuse large B-cell lymphoma 
(Figs. 4A to 4D).
 The patient completed the disease staging with cerebral 
spinal fluid analysis, bone marrow biopsy, thoraco-abdomi-
no-pelvic CT scan, and positron emission tomography (Fig. 
5). All the tests revealed that the lesion was restricted to the 
CNS. Viral serologies were also negative. The International 
Extranodal Lymphoma Study Group (IELSG) prognostic 
score was 2 (elevated cerebrospinal fluid proteins and el-
evation of serum lactate dehydrogenase, corresponding to 
Figure 3 – MRI in August 2014. Axial T1 weighted image with gadolinium enhancement shows enlargement of the right caudate nucleus 
periventricular lesion (A). Axial T1 weighted image with gadolinium enhancement confirms regression of the lesion in the anterior wall of 
the third ventricle (B). Axial diffusion (ADC map) showing restriction to diffusion in the right caudate lesion (C). Axial diffusion (b-1000 map) 
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an intermediate risk).
 Chemotherapy was initiated with high-dose cytarabine 
+ high-dose methotrexate + rituximab and radiotherapy (45 
gray fractionated in 4.5 gray/day, 5 times/week). 
The patient was still alive at 32 months after the histological 
diagnosis, with the CNS lymphoma in complete remission. 
DISCUSSION 
 Differential diagnosis of a vanishing sellar/suprasellar 
lesion should always include a demyelinating lesion. Other 
possible causes are inflammatory diseases such as au-
toimmune hypophysitis, pituitary apoplexy with interval 
resolution, and pituitary macroadenoma.15 Autoimmune 
hypophysitis is more frequent in young female patients, 
and can regress with corticosteroid treatment.15 Pituitary 
apoplexy is a clinical syndrome in which more than 80% 
of the cases present with sudden-onset headaches. This 
did not occur in our case, but is also a cause of regression 
in pituitary adenomas.15 There are two cases reported in 
the literature of spontaneous regression of a pituitary mac-
roadenoma. One of these experienced regression in 3.5 
months, but this patient had only one lesion and not multiple 
lesions as our case.15 
 In our report, there was no histological diagnosis for the 
vanishing sellar/suprasellar lesion but it is highly probable 
that it corresponds to the same diagnosis of the caudate 
Figure 4 – Histology of the right caudate nucleus lesion. Hematoxylin eosin with diffuse neoplasic cells with scarce cytoplasm and bulky 
nuclei (A). Immunocytochemistry demonstrating positivity for CD 20, ACL and BCL6 (B, C, D).
C D
BA
Figure 5 – Positron emission tomography in October 2014 showing disease located in the right caudate nucleus.
CA DB
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lesion. 
 As already mentioned, the most probable explanation 
for a lymphoma that vanishes without corticosteroid treat-
ment is a concomitant viral infection leading to an increased 
number of body natural killer cells, which attack the tumor 
cells. 
 To the best of our knowledge and based on a PubMed 
search of the literature regarding spontaneous remission of 
central nervous system lymphoma up to June 2017, there 
are only 11 case reports of spontaneous remission/relaps-
ing of central nervous system lymphomas. In some of those 
reports, other conditions like multiple sclerosis were sus-
pected because of the spontaneous regression on diag-
nostic imaging and the diagnosis and treatment were also 
delayed, which affected the overall survival (Table 1). 
CONCLUSION
 Despite being extremely rare, there are cases reported 
of spontaneous remission and relapse of brain CNS lym-
phomas.
 This case allows us to infer that differential diagnosis of 
primary CNS lymphoma should always be considered when 
a patient presents with a brain lesion that shows imaging 
and clinical spontaneous remission and relapse. These pa-
tients should be followed at short intervals, and in suspi-
cious cases, a histological diagnosis must be obtained as 
soon as possible to avoid delays in diagnosis and treat-
ment. 
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